Zydus Lifesciences gets USFDA’s final nod for Doxepin Tablets

17 Aug 2023 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Doxepin Tablets, 3 mg and 6 mg (USRLD: Silenor Tablets, 3 mg and 6 mg). Doxepin is used to treat a certain sleep problem (insomnia). It is expected to help stay asleep longer and reduce the number of times a person wakes up during the night. Doxepin belongs to a class of drugs known as tricyclic antidepressants. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.

Doxepin Tablets, 3 mg and 6 mg had annual sales of $43.4 million in the United States (IQVIA MAT June 2023). The group now has 376 approvals and has so far filed over 444 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×